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Abstract 
 
 
SCHIZOPHRENIA CANDIDATE GENES STUDY 
By Grace Hyeiwon Lee, M.S. 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Masters at 
Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director: Xiangning Chen 
Associate Professor, School of Medicine 
 
 
 
Schizophrenia is a debilitating disorder caused by the interaction of genetic and 
environmental factors. In this study, we identified candidate genes and single nucleotide 
polymorphisms from two genome-wide association studies, GAIN and CATIE. Nine 
SNPs representing four candidate genes were selected for replication studies with our 
Irish samples: Irish Case-Control Study of Schizophrenia (ICCSS), the Irish Study of 
High-Density Schizophrenia Families (ISHDSF), and the Irish Trio Study of 
Schizophrenia (ITRIO). In the ITRIO sample, rs4704591 (CMYA5 gene) showed 
nominal significance (p = 0.0447947). Combining ICCSS, ISHDSF, and ITRIO samples 
for rs4704591 increased sample size and power and yielded a p-value of 0.00388. This 
marker remained significant after Bonferroni correction for 9 markers genotyped in this 
study. CMYA5 gene binds to dysbindin protein in muscle. The dysbindin gene may 
influence glutamatergic neurotransmission, which has been suspected of being a 
mechanism by which the pathophysiology of schizophrenia is manifest. Our data suggest 
CMYA5 gene may be associated with schizophrenia in Caucasian subjects.
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CHAPTER 1: INTRODUCTION 
1.1. Schizophrenia 
 1.1.1 Epidemiology & Significance of Schizophrenia 
 Schizophrenia (SZ) is a chronic, severely debilitating brain disorder with a 
lifetime risk of approximately 1%. The National Institute of Mental Health (NIMH) 
reports the number of Americans affected by SZ to be approximately 2.4 million (NIMH, 
2009). Factors such as the gravity of physical and emotional suffering undergone by 
patients and caretakers are important in determining the significance of a disorder. In 
addition, the economic burden caused by a disorder is also noteworthy. A study (Wu et 
al., 2005) reported the overall U.S. 2002 cost of SZ was estimated to be $62.7 billion. Of 
the total, excess direct health care cost contributed $22.7 billion ($7.0 billion outpatient, 
$5.0 billion drugs, $2.8 billion inpatient, and $8.0 billion long-term care). The total 
indirect excess costs contributed $32.4 billion, and the total direct non-health care excess 
costs contributed $7.6 billion. Only 10% to 15% of people with SZ are estimated to be 
able to maintain full-time employment, which led to the direct excess cost due to 
unemployment being the largest component of overall SZ excess costs. There is no 
consensus on geographic and temporal variations in incidence rates. Some claim SZ 
occurs in diverse populations over the world at comparable rates (Jablensky et al., 1992), 
and that its incidence rate has remained similar over the past two centuries (Jablensky & 
Kalaydjieva, 2003). Others, concluded up to fivefold variation is seen in world-wide 
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incidence of SZ (McGrath et al., 2004). Regardless, the prevalence of SZ in the U.S. and 
the world establishes SZ as a vital area of research efforts. 
 SZ typically manifests in late adolescence or in early adult life. Females tend to 
have a later onset than males, and females also tend to have a milder form of the disorder 
with a better outcome than males. McGrath et al. (2004) reported the occurrence of SZ to 
be higher among males with a mean rate ratio of 1.4. SZ is also known to prevail to a 
greater extent in cities. Poverty, poor nutrition, inadequate healthcare and education are 
thought to attribute to the risk-increasing effects of urbanization. A certain migrant 
groups also show a higher incidence of SZ especially if they are relatively isolated with 
their own ethnic group in a small minority. Some of the well-replicated findings are with 
African-Caribbean migrants in the United Kingdom and Norwegians in the United States 
(Murray et al., 2008). 
 1.1.2. Symptoms of Schizophrenia 
 Schizophrenia is a multi-dimensional disorder with variable phenotype 
expressions (Figure 1). Such heterogeneity is in part determined by the age of onset, and 
patients’ predominant symptoms may change as the disease progresses. Nothing the 
various materializations of the disorder, SZ is generally characterized by symptoms of 
psychosis such as hallucinations and delusions, and they are a major component of the 
diagnostic criteria for SZ in the Diagnostic and Statistical Manual of Mental Disorders, 
4th edition (DSM-IV) (Figure 2). Hallucinations are generally auditory sensation in which 
patients believe they hear abusive or derogatory comments, although somatic or visual 
sensations manifest in some cases as well. Delusions, or false beliefs, range from 
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believing oneself to be under surveillance as a part of religious or political conspiracy to 
believing one’s thoughts to be controlled by an evil will. Most delusions are of a paranoid 
nature, and some are religious, grandiose, or sexual. Hallucinations and delusions are 
termed positive symptoms, and they become more resistant to antipsychotic drug 
treatments with each succeeding schizophrenic episode. SZ patients also show derailment 
of thought and incoherent, illogical speech (Murray et al., 2008). 
 Negative symptoms of SZ include: social withdrawal, apathy, loss of motivation, 
slowness of thought and action, and poverty of thought and speech. As suggested by 
manifestations, negative symptoms accompany cognitive impairment especially in 
memory, attention and executive functions. Negative symptoms are prominent in chronic 
patients, and they accumulate gradually. These symptoms are harder to measure than 
positive symptoms, but they tend to be more persistent and are related to worse 
prognostics for patients (Murray et al., 2008). SZ patients also experience mood 
symptoms which make them feel hopeless and suicidal. In fact, research indicates that at 
least 5-13% of schizophrenia patients die by suicide, with the higher end of the range 
being the more accurate estimate (Pompili et al., 2007). 
 1.1.3. Etiology of Schizophrenia 
 Schizophrenia is caused by the interaction of genetic and environmental factors 
(Figure 3), and the genetic contribution is regarded as the most important of the known 
etiologic factors. The heritability of SZ liability is estimated to be up to 85%. The main 
sources of evidence for the genetic predisposition are studies of relatives, twin studies, 
and adoption studies (Murray et al., 2008). In a study with all patients with SZ on the 
4 
 
Roscommon County Case Register in Ireland, Kendler et al. (1993) found the lifetime 
risk of SZ for the first-degree relative of SZ patients to be 6.5% and that for the relatives 
of control subjects to be 0.5%. Other studies also report a higher incidence of SZ with 
relatives of SZ patients. According to NIMH, although SZ occurs in about 1 percent of 
the general population, it occurs at around 10 percent of the people with a first-degree 
relative with the disorder. NIMH also states people with a second-degree relative with SZ 
are also more likely than the general population to develop SZ (NIMH, 2009). Twin 
studies have further established genetic contributions to SZ. A monozygotic twin of a SZ 
patient has 41 to 65 percent chance of developing the disorder. The concordance rate is 0 
to 28 percent for dizygotic twins (Cardino & Gottesman, 2000). Such studies firmly 
establish the role of genetics in SZ, but it is important to note that although SZ is 
mediated by genetics, it is not determined by it. In addition to the genetic factor, various 
environmental risk factors have been suggested. Although environmental risk factors 
operate throughout the life course, some believe the risk factors in action early in life –
before or shortly after birth—cause abnormalities in the nervous system formation 
making an individual vulnerable to psychosis. These early inflictions include prenatal 
exposure to viruses, malnutrition in the womb, pregnancy complications such as bleeding, 
diabetes, and pre-eclampsia, complications of delivery such as uterine atony, emergency 
C section and asphyxia, and abnormal fetal growth and development such as low birth 
weight, and small head circumference. Neurodevelopmental abnormalities caused by 
early environmental insults may be aggravated and may lead to brain dysfunction by 
additional environmental factors in childhood or adolescence. Such factors include social 
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isolation, child abuse, and use of cannabis or other street drugs (Murray et al., 2008). In 
sum, genetic factors may predispose an individual to SZ, and such individual may 
become schizophrenic upon encountering environmental stress factors at various stages 
of his life. 
  1.1.3.1 Genetic Etiology of Schizophrenia 
 According to Kendler et al. (1993), what is transmitted through genes include 
predisposition to minor cognitive deficits, poor psychosocial functioning, suspiciousness 
and oddness and also to psychotic illness, schizotypal personality and paranoid 
personality disorder. In addition, not only the liability to SZ but also the specific clinical 
character of the disorder has been attributed to familial influence (Fanous & Kendler, 
2005). The major focus of the genetics research on SZ has been on identifying the genes 
that are associated with SZ. The genetics research on SZ has come a long way since its 
embarkation in 1916, and more than 2000 association studies involving 500 genes have 
been reported for either positive or negative associations with SZ (Sun et al. 2008). 
Although the genetic etiology and pathogenesis of SZ remains largely elusive to date, 
linkage studies suggest that no one gene exists that increases the risk of SZ by more than 
three-fold, meaning that there may be a number of susceptibility genes (Murray et al., 
2008). In fact, multiple genes and alleles in various combinations may contribute to the 
genetic background of the disorder, with a proportion of the transmitted genotypes 
remaining clinically unexpressed (Gottesman & Bertelsen, 1989). 
 Based on the polygenic multifactorial model of schizophrenia, many putative 
susceptibility genes have been found, including: DRD3, 5HT2a, DISC1, DISC2, COMT, 
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ProDH, RGS4, DTNBP1 (dysbindin), NRG1 (neuregulin 1), G72 and DAAO. The list of 
possible susceptibility genes is ever expanding, but the results of the studies showing 
positive associations with SZ are not well-replicated (Murray et al., 2008). It should also 
be considered that not all identified candidate genes may be susceptibility genes, meaning 
that studies suggest some genes may influence clinical features of SZ without changing 
the susceptibility to SZ. Such “modifier genes” have been demonstrated to be present in 
other diseases as well. Another challenge of unraveling the genetic etiology of SZ stems 
from possible genetic mechanisms that may alter the expression of correctly identified 
genes such as epistatsis, pleiotropy, imprinting, genetic heterogeneity, and phenocopies 
(Fanous & Kendler, 2005). Detailed discussion of all such genetic models of SZ is 
beyond the scope of this paper, but copy number variation (CNV) in particular, is an area 
of investigation for its undisputed pathogenic role in SZ (Williams et al., 2008).  
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The Complexity of Symptoms in Schizophrenia 
 
Positive Symptoms 
• Delusions 
• Hallucinations 
• Disorganized speech 
• Catatonia 
Negative Symptoms 
• Apathy 
• Social withdrawal 
• Loss of 
motivation 
Mood Symptom 
• Suicidality 
• Hopelessness 
• Dysphoria 
Cognitive Symptoms 
• Attention 
• Memory 
• Executive functions 
Figure 1. The Complexity of Symptoms in Schizophrenia. Schizophrenia is a 
multi-dimensional disorder with variable phenotype expressions. It is believed that 
a variety of molecular pathways involving many different susceptibility genes 
contributes to this heterogeneity. 
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1. At least two of A (only one of A required if delusions are 
bizarre or hallucinations consist of running commentary 
or discussing voices) 
2. Continuous signs of disturbance for at least 6 months 
with at least 1 month of acute phase symptoms (A) 
3. Exclusions: the disorder must not be attributable to 
schizoaffective or mood disorder with psychotic features, 
the direct effects of a substance or a general medical condition 
4. Social/occupational dysfunction (below the level of 
expected functioning) 
 
A 
• Delusions 
• Hallucinations 
• Disorganized speech 
• Grossly disorganized or catatonic behavior 
• Negative symptoms 
 
 
 
Figure 2. Diagnostic criteria for schizophrenia from DSM-IV-TR. 
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Etiologic Pathway of Schizophrenia 
 
 
 
Neurodegeneration & 
Schizophrenia
Neurodevelopmental 
Abnormalities 
Psychosis 
Early environmental risk factors 
• Prenatal viral infection 
• Pregnancy stress/factors 
9 Malnutrition in womb 
9 Delivery complications 
9 Abnormal fetal growth
Later environmental risk factors 
• Social isolation/stress 
• Child abuse 
• Marijuana/Cannabis use 
Further brain dysfunction 
& Schizophrenia
Genetic Predisposition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Etiologic Pathway of Schizophrenia. Schizophrenia is caused by the 
interaction of genetic and environmental factors.
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1.2. Genome-wide Association Studies 
 
  1.2.1. What is a Genome-wide Association Study? 
 A genome-wide association study, GWAS, emerged as the completion of the 
Human Genome Project (2003) and the International HapMap Project (2005). These 
projects provided computerized databases containing the reference human genome 
sequence, a map of human genetic variation, and new technologies that enable analyses 
of whole-genome samples for genetic variations (NHGRI, 2009).  
The GWAS and association studies in general are conducted using two groups of 
participants: people with the disease being studied, and similar people without the disease. 
Once the participants’ blood or cells are obtained, each person’s genome is purified and it 
is surveyed for selected markers of genetic variation called single nucleotide 
polymorphisms, or SNPs. If a certain genetic variation is observed significantly more 
frequently in people with the disease, it is said to be associated with the disease. The 
associated variants have their value in locating the regions of the human genome in which 
disease-causing problems reside (National Human Genome Research Institute [NHGRI], 
2009). 
What distinguishes the GWAS from other association studies is that the GWAS 
allows finding of genetic variations associated with particular diseases by rapidly 
scanning markers across the genome – the complete set of DNA –, of many individuals. 
This allows researchers to sample 500,000 or more SNPs from each subject, enabling 
them to capture variations across the genome at uniform distances between SNPs. The 
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ability to scan the entire genome, in turn, makes the GWAS a hypothesis-free study, in 
which candidates identified are more objective.  
In the early stages, genetic association studies identified genes responsible for 
numerous monogenic disorders such as CFTR (cystic fibrosis), Huntingtin (Huntington’s 
disease), BRCA1 (breast and ovarian cancer) and so forth. However, such approach to 
identify genes in multigenic diseases – diseases caused by the combined effect of 
multiple polymorphisms in a number of genes – has faced more challenges (Barnes, 
2007). The GWAS is considered to have the potential to yield substantial insights into 
various disorders including psychiatric disorders. Its power to detect small effects without 
specific knowledge of pathogenesis has especially been useful for researching the 
genetics of complex disorders (Williams, Owen & O’Donovan, 2009). 
 1.2.2. Genome-wide Association Studies of Schizophrenia 
 Association studies in SZ have evolved in parallel with GWAS technology, and 
there have been a number of findings based on positional approaches with compelling 
evidence. Such findings are likely to include true susceptibility genes, but evidence has 
not been unequivocal, especially in terms of specific alleles or haplotypes. There have 
been six published GWASs of schizophrenia up to date, of which three have been based 
on DNA pooling and one has been limited to non-synonymous SNPs (Williams et al., 
2009). These studies reported a number of significant associations with various genes 
including CSF2RA and SHOX (Mah et al., 2006), ZNF804A (O’Donovan et al., 2008), 
and reelin (Shiftman et al., 2008). And yet, no findings from the published GWAS studies 
were able to report a locus that reaches genome-wide levels of significance in any single 
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or combined study until recently (Dudbridge & Gusnanto, 2008). In 2009, however, The 
International Schizophrenia Consortium (2009) reported the major histocompatibility 
complex on chromosome 6 to have reached GWAS significance.  
Williams et al. (2009) states that more robust results for other disorders have 
come from GWAS applied to large patient and control samples and also from follow-up 
analyses in even larger samples. Such approaches are being applied to SZ in recent years 
and have yielded some promising results. The success of the future SZ GWAS studies 
depends largely on assembly of large, well-phenotyped patient samples, effective 
collaboration and sharing of patient resources, and the ability to handle and analyze 
increasingly large and complex data sets.  
1.3. Hypothesis of the Study 
 GWAS has the potential to identify genes involved schizophrenia. Although most 
published data sets did not identify candidate genes in these individual studies, these 
datasets contain valuable information that can be extracted to identify promising 
candidates. We hypothesized that each individual study of GWAS had useful information 
and that by combining multiple datasets we could increase our probability of successfully 
identifying promising candidate genes. To test this hypothesis, we selected all markers 
with p-values <= 0.05 from both GAIN and CATIE studies, and matched them against 
each other. We further refined our selection using linkage disequilibrium data from 
neighboring markers, the function of the markers and relevance to schizophrenia in 
PubMed databases. Using these processes, we selected a total of 9 markers in 4 genes and 
tested their association in our independent Irish samples. 
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CHAPTER 2: MATERIALS & METHODS 
2.1. Subjects 
 All samples used were obtained and organized by other researchers prior to the 
current study. 
 2.1.1. The Irish Study of High-Density Schizophrenia Families (ISHDSF) 
sample 
 The ISHDSF sample was collected in Northern Ireland, the United Kingdom, and 
the Republic of Ireland. Phenotypes were assessed using DSM-III-R. The diagnoses were 
formed into a hierarchy of 10 categories reflecting the probable genetic relationship of 
these syndromes to classic SZ. This hierarchy consisted of three definitions of affection: 
1) Narrow – categories D1 and D2, or “core schizophrenia” – schizophrenia, poor-
outcome schizoaffective disorder and simple schizophrenia; 2) Intermediate – categories 
D1-D5, or a narrow definition of the schizophrenia spectrum, adding to the narrow 
definition schizotypal personality disorder, schizophreniform disorder, delusional 
disorder, atypical psychosis and good-outcome schizoaffective disorder; 3) Broad – 
categories D1-D8, including all disorders that significantly aggregated in relatives of 
schizophrenic probands in the Roscommon Family Study (Kendler et al., 1993) and 
adding to the intermediate definition mood incongruent and mood congruent psychotic 
affective illness, and paranoid, avoidant and schizoid personality disorder. The final 
inclusion criteria for pedigrees in the ISHDSF sample required two or more first, second, 
or third-degree relatives with a diagnosis of D1-D5, one or more of whom had a D1-D2 
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diagnosis. The sample contained 273 pedigrees and about 1350 subjects had DNA sample 
for genotyping. Of them, 515 were diagnosed with the narrow definition (351 males and 
164 females), 634 were diagnosed with the intermediate definition, and 686 were 
diagnosed with the broad definition. Of these, 522 were used as cases in this study, and 
869 were used as controls. Detailed descriptions of the sample were published previously 
(Kendler et al., 2000).  
 2.1.2. The Irish Case-Control Study of Schizophrenia (ICCSS) sample 
 The ICCSS sample was collected in Northern Ireland, the United Kingdom and 
the Republic of Ireland.  In this study, we used 657 (436 males and 221 females) affected 
subjects and 411 (233 males and 178 females) control subjects. The affected subjects 
were selected from in-patient and out-patient psychiatric facilities in the Republic of 
Ireland and Northern Ireland. Subjects were eligible for inclusion if they had a diagnosis 
of schizophrenia or poor-outcome schizoaffective disorder by DSM-III-R criteria, and the 
diagnosis was confirmed by a blind expert diagnostic review. Control subjects, selected 
from several sources, including blood donation centers, were included if they denied a 
lifetime history of schizophrenia. However, the fact that control subjects were not 
screened by clinicians is a potential weakness in the study design. Both case and control 
subjects were included only if they reported all four grandparents as being born in Ireland 
or the United Kingdom. Family history (FH), based on the family-history research 
diagnostic criteria (Endicott, Andreasen & Spitzer, 1978), was assessed by clinical 
interview of probands and their relatives. Subjects having a first or second-degree relative 
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diagnosed with schizophrenia were classified as FH positive. In the ICCSS sample, there 
were 117 subjects (71 males and 46 females) classified with positive FH of schizophrenia. 
 2.1.3. The Irish Trio Study of Schizophrenia (ITRIO) sample  
 The ITRIO samples were collected in the same period as the ICCSS sample. The 
inclusion criteria and symptom ascertainments were identical to those of ICCSS samples. 
ITRIO samples included probands and their fraternal and maternal parents. Of the 187 
families from whom samples were collected, 26 families had two affected subjects; two 
families had three affected subjects; and the remainder had a single affected subject. In 
addition, there were 29 subjects who had another first or second-degree relative 
diagnosed with schizophrenia. DNA samples from a total number of 216 affected 
subjects and 372 unaffected subjects were used for the current study.  
2.2. Genome-wide Association Study Datasets 
 2.2.1. The Genetic Association Information Network Study 
 The Genetic Association Information Network (GAIN) is a public-private 
partnership funding genome-wide association studies established by the Foundation for 
the National Institute of Health. The GAIN’s initial study to genotype existing research 
studies in six major common diseases was completed in 2007, and the resulting data are 
being deposited in a database that is available to the research community upon approved 
request. The network’s initial efforts focused on Attention Deficit Hyperactivity Disorder, 
diabetic neuropathy in type I diabetes, major depression, psoriasis, schizophrenia, and 
bipolar disorder (Foundation for the National Institute of Health, 2008).  
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 For the current study, the GAIN study data was obtained. The data included 
information for 906600 markers for 4505 individual samples. Only the Caucasian subset 
of the GAIN’s samples was used for this study. There were 2601 subjects (1172 cases, 
1378 controls, 51 missing phenotype; 1485 males and 1115 females) in this subset. Along 
with the CATIE study data, the GAIN study data was used extensively in the current 
study as a method of selecting candidate genes and markers. 
 2.2.2. The Clinical Antipsychotic Trials of Intervention Effectiveness Study 
 The Clinical Antipsychotic Trials of Intervention Effectiveness Study, funded by 
the National Institutes of Health’s National Institute of Mental Health, is a clinical trial 
comparing the effectiveness of older (first available in the 1950s) and newer (available 
since the 1990s) antipsychotic medications that are used to treat schizophrenia (National 
Institute of Mental Health, 2009). The study’s data is available to the research community 
upon approved request. The CATIE study’s 1492 participants (741 cases and 751 
controls) included SZ patients across the United States being treated in a variety of 
settings. For the current study, the Caucasian subset of the CATIE’s samples was used. 
There were 492 cases and 523 controls (771 males and 244 females) in this subset, 
totaling 1015 subjects. The CATIE study data obtained included information for 495172 
markers. The CATIE study dataset was used in the current study for selecting candidate 
genes and markers. 
 Participants for the CATIE study were eligible to be included in the study if all of 
the following criteria were met: 1) 18-65 years old; 2) DSM-IV diagnosis of 
schizophrenia; 3) adequate capacity to consent. They were excluded in the following 
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cases: 1) intolerance of failure to respond to one of the treatments; 2) diagnoses of 
schizoaffective disorder, mental retardation, pervasive developmental disorder, delirium, 
dementia, amnesia; 3) first episode of schizophrenia; 4) women currently pregnant or 
breast-feeding; 5) have a serious and unstable medical condition (Lieberman et al., 2005). 
The details of ascertainment and demographics of the CATIE subjects have been 
published by Lieberman et al. in 2005.  
2.3. Management of GWAS Data 
 For the purpose of managing the contents of the GAIN and CATIE datasets to fit 
the needs of the current study, a genomic analysis software, PLINK (v. 1.05) (Purcell, 
2007), was used. Using PLINK, each of the two GWAS datasets were compartmentalized 
into two different datasets according to the subject’s race (white or black). This was done 
as ISHDSF, ICCSS, and ITRIO samples are all of Caucasian descent. The CATIE study 
data yielded 1015 white subjects and 477 non-white subjects; the GAIN study data 
yielded 2601 white subjects and 1904 black subjects. The CATIE study included samples 
whose races are neither Caucasian nor black, and thus, the term “non-white” was used. 
2.4. Selection of Genes of Interest 
 In this study, an approach was taken in which a range of candidate genetic 
markers were pre-selected if they met the following criteria: 1) markers are included in 
both the GAIN study dataset and also in the CATIE study dataset, and 2) allelic p-values 
are less than 0.05 in both datasets. Allelic p-values were calculated from only Caucasian 
samples in both GAIN and CATIE datasets. From this process, 1229 markers covering 
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315 genes were pre-selected. Out of 1229 markers, 682 markers were not a part of known 
genes; they were precluded from further analyses.  
 The preceding part of the study confided in subjectivity, as no systematic scoring 
strategy was used. The following were considered to choose candidate genes from the 
315 pre-selected genes:  
1) Current knowledge regarding location of gene expression & functions of the gene: 
Upon literature search of individual genes, genes with known biological functions in the 
nervous system were given more significant consideration for biological plausibility. 
2) Physical proximity to other likely candidate genes: Significant consideration was given 
also to genes that are physically close to other pre-select genes. 
3) Number of markers from a particular gene that are included the pre-selected markers: 
Genes that contain numerous (4 or more) markers from the pre-select marker list were 
placed in a higher priority list. 
 4) Gene region covered by the markers in the pre-selected list (i.e. intron, UTR, near 
gene, etc.): A special interest was given to genes that contain markers with missense 
mutations. Genes whose pre-select markers are confined to the untranslated region (UTR) 
or near-gene regions were given relatively less consideration. 
5) Previously reported association with schizophrenia or other mental disorders: Genes 
that have been studied related to schizophrenia or other mental disorders –bipolar 
disorder, Alzheimer’s disease, and Parkinson’s disease in particular- were given a special 
consideration.  
2.5. Marker Selection and Genotyping 
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 A total of nine markers from four genes that had shown significant associations (p 
< 0.05) with SZ from GAIN and CATIE white samples were selected. These markers 
covered the following genes: Protein Tyrosine Phosphate Non-receptor Type 21 
(PTPN21), Echinoderm Microtubule-Associated Protein-Like 5 (EML5), 
Cardiomyopathy Associated 5 (CMYA5), and Nitric Oxide Synthase 1 Adaptor Protein 
(NOS1AP). All markers contained in the GWAS datasets from each selected candidate 
gene were extracted using PLINK (v. 1.05) (Purcell, 2007). PLINK (v.1.05) was also 
used to analyze the associations of these markers in samples from the GWAS datasets. 
Analyses were done via linear regression with the CATIE dataset, and via allelic 
associations for the GAIN dataset. Using the linear regression with the CATIE dataset 
allowed for covariates to be accounted for. The linkage disequilibrium (LD) for GAIN 
and CATIE datasets was examined for each candidate gene using the HAPLOVIEW 
program. Multiple factors were taken into consideration in electing SNPs for individual 
candidate genes. These include the number of markers showing nominal significance, the 
LD of these markers and their frequencies, and the location and nature of the 
polymorphisms (i.e. whether these markers change an amino acid, splicing site, 
transcription factor binding site etc).  
 All markers were typed using the TaqMan method. In the TaqMan method, the 
TaqMan probe consists of two types of fluorophores, which are the fluorescent parts or 
reporter proteins. While the probe is attached or unattached to the template DNA and 
before the polymerase acts, the quencher fluorophore reduces the fluorescence from the 
reporter fluorophore. After the denaturation of template DNA reaction cools, the TaqMan 
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probe binds to its specific piece of the template DNA, and the primers anneal to the DNA. 
Taq polymerase adds nucleotides to remove the TaqMan probe from the template DNA, 
which separates the quencher (at 3’-end) from the reporter (at 5’-end), and the reporter 
emits its energy which is quantified using a computer (Livak, 1999). SNPs typed by this 
method were either validated assays or custom designed assays developed by Applied 
BioSystems Corporation (Foster City, CA). All markers were genotyped for the ICCSS 
and ISHDSF samples, and only the markers for the CMYA5 gene were genotyped 
additionally for the ITRIO sample. All genotypes were scored using a semi-automated 
Excel template developed in our lab (van den Oorde, et al., 2003). All markers typed 
were checked for deviation from the Hardy-Weinberg Equilibrium (HWE) and 
Mendelian errors by the PEDSTATS program (Wigginton et al., 2005).  
2.6. Statistical Analyses 
 The ISHDSF sample was analyzed using the pedigree disequilibrium test (PDT) 
(Martin et al., 2000) as implemented in the UNPHASED program (version 2.4, 
PDTPHASE module) (Dudbridge, 2003) for single marker associations. Single marker 
association tests compare frequencies of particular alleles, or genotypes, in affected and 
unaffected subjects. In these analyses, both vertical and horizontal transmissions were 
included. The p-values reported were based on weighing all families equally (the ave 
option in the program). For the ICCSS sample, the new version (v. 3.1) of the 
UNPHASED program (Dudbridge, 2008) was used to analyze single marker associations. 
For the ITRIO sample, since all samples were from nuclear families with no unaffected 
siblings, transmission disequilibrium test (TDT) as implemented in the TDTPHASE 
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module of the UNPHASED program was used. In the combined analyses of discovery 
samples (GAIN & CATIE), single marker associations were obtained using the 
linear/logistic regression p-value platform of the PLINK (v.1.05) program. For the 
combined analyses of replication samples (ICCSS + ISHDSF + ITRIO), single marker 
associations were performed using the UNPHASED program (v. 3.10). 
 Odds ratio and confidence interval were computed for all samples using version 
3.1 of the UNPHASED program, as version 2.4 did not provide the information needed 
for the computation in the ISHDSF and ITRIO samples. In all samples, the odds ratio 
compared case to control allele frequencies. The test statistic is χ2 = [(a/(a+c))/(b/(b+d))], 
where a = number of major alleles present in cases, c = number of minor alleles present 
in cases, b = number of major alleles present in controls and d = number of minor alleles 
present in controls. The odds ratio was constructed as (a/c)/(b/d). 
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CHAPTER 3: RESULTS 
3.1. Selected Candidate Genes 
 3.1.1. Protein Tyrosine Phosphate Non-receptor Type 21 (PTPN21) Gene 
 Seven markers from the PTPN21 gene on Chromosome 14q31.3 were present in 
the pre-selected marker list (Table 1). PTPN21 and EML5 genes, also one of the selected 
candidate genes, are a relatively small distance away in chromosomal position. The two 
genes are a 60 kb away, having ZC3H14 as the only gene between them (Figure 4). 
PTPN21 and EML5 were the only genes aggregated in the same region of the genome 
with 4 or more markers for each gene present in the pre-selected marker list. A number of 
SZ studies to date have uncovered specific regions of the genome spanning multiple 
genes to be liable for the disease. Such specific regions of the genome include 5q21-31 
(Pimm et al., 2005; Petryshen et al., 2005; Chen et al., 2006; Chen et al., 2007), 22q12-
q13, 8p22-p21, 6p24-p22, 13q14-q32, and 6q21-q22 (Riley & Kendler, 2006). Thus, the 
physical proximity of the two genes, PTPN21 and EML5, presented a possibility of 
discovering a novel region of the genome implicated with SZ. 
 PTPN21 is a member of the protein tyrosine phosphatase (PTP) family. PTP 
proteins are known to be signaling molecules regulating various cellular processes such 
as cell growth, mitotic cycle, differentiation, and oncogenic transformation. PTPN21, 
specifically, has been shown to interact with a member of Tec tyrosine kinase, 
BMX/ETK. PTPN21 has also shown evidence for playing a role in liver regeneration and 
spermatogenesis (Zeitlin et al., 2007). Although biological roles played by PTPN21 
known to date do not appear to provide obvious links to SZ, many cellular processes that 
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PTP family of proteins regulate have been shown to be irregular in SZ. For instance, 
McCurdy et al. (2006) reported significantly more mitosis in SZ patients compared to 
controls. Their microarray data also suggested alterations to the cell cycle in SZ. This 
suggests a possibility that PTPN21 may have an effect on the cell cycle in SZ. 
 3.1.2. Echinoderm Microtubule-Associated Protein-Like 5 (EML5) Gene 
 The EML5 gene, located on Chromosome 14q31.3, contained six markers in the 
pre-selected marker list (Table 1). This gene has been shown to be expressed in the rat 
brain, especially at high levels in the hippocampus, cerebellum, and olfactory bulb. 
EML5 has homology to EMAP, the major microtubule-associated protein in dividing sea 
urchin embryos. EML5 contains WD40 and HELP domains that have been suggested to 
be involved in microtubule binding. It has been suggested that like other EMAP-like 
proteins, EML5 plays a role in the regulation of cytoskeletal rearrangements during 
neuronal development and in adult brain (O’Conner et al., 2004). The gene being 
expressed in the brain made it a more attractive candidate gene. Also, studies have 
implied involvement of other genes regulating cytoskeletal arrangements with SZ 
(Hennah & Porteous, 2009; Kleppisch & Feil, 2009) which provides further evidence for 
the relevance of EML5 to SZ. Along with EML5’s proximity to PTPN21, as discussed 
above, its biological significance contributed to its potential to be a gene that may be 
implicated with SZ. 
 3.1.3. Cardiomyopathy Associated 5 (CMYA5) Gene 
 The CMYA5 gene, located on Chromosome 5q14.1, contained three markers in 
the pre-selected marker list (Table 1). The CMYA5 gene is a muscle-specific member of 
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the TRIM superfamily. Studies have shown its expression in cardiac and skeletal muscle. 
It is involved in protein kinase A signaling and vesicular trafficking. So far, the gene has 
been reported in studies involving Duchenne muscular dystrophy and cardiac disease 
(Sarparanta, 2008). CMYA5 was also shown to be a binding partner for dysbindin protein 
in muscle, and it is intriguing to note that dysbindin, involved in the biogenesis of 
lysosome-related organelles, has been receiving much attention as a key SZ susceptibility 
factor (Benson, Tinsley, & Blake, 2004). The dysbindin gene may influence 
glutamatergic neurotransmission, which has long been suspected of being a mechanism 
by which the pathophysiology of SZ is manifest (Sodhi, Wood, & Meador-Woodruff, 
2008). As previously identified SZ susceptibility genes have shown biological pathways 
involving multiple genes to be engaged in pathogenic mechanisms of SZ, CMYA5 gene’s 
relation to dysbindin gene offers a motive for further investigation of CMYA5 as a 
candidate gene.  
 Out of the three markers of the CMYA5 gene in the pre-selected marker list, two 
of them consisted of missense mutations. This is significant because the likely outcome 
of proteins encoded with missense mutations can be expected to be non-functional. In 
fact, such mutations are responsible for a number of diseases such as sickle-cell disease 
and amyotrophic lateral sclerosis. In SZ research, a widely studied candidate gene DISC1 
contains missense mutations that give rise to phenotypes in SZ (Millar et al., 2007). Out 
of the 1229 total markers in the pre-selected marker list, there were 11 missense 
mutations total. There were only two genes that contained 2 or more markers with 
missense mutations, and they were PTPN21 and CMYA5. The prevalence of missense 
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mutations in pre-selected markers presented a case for possible protein dysfunctions that 
has an effect on SZ.  
 3.1.4. Nitric Oxide Synthase 1 Adaptor Protein (NOS1AP) Gene 
 The NOS1AP gene, located on Chromosome 1q22, contained six markers in the 
pre-selected marker list (Table 1). This gene encodes a cytosolic protein that binds to the 
signaling molecule, neuronal nitric oxide synthase (nNOS), which regulates neuronal 
nitric-oxide (NO) synthesis (Jaffrey et al., 1998). Chromosome 1q22 is a locus initially 
identified as of interest from linkage studies of SZ. Recent studies have implicated the 
NOS1AP gene in susceptibility to SZ in various ethnic samples (Bruzustowicz et al., 
2004; Zheng et al., 2005; Xu et al., 2005). However, replication studies have been 
inconsistent (Fang et al., 2008; Puri et al., 2006). After the completion of the current 
study, more studies linking NOS1AP with SZ susceptibility were published; Kremeyer et 
al. (2009) found eight SNPs in the NOS1AP gene to be statistically significant in SZ 
samples from South America. Also, Wratten et al. (2009) found the A allele of 
rs12742393 to be a risk allele associated with SZ via enhancing transcription factor 
binding and gene expression. The presence of NOS1AP gene markers with significant p-
values in the pre-select marker list made the gene an appealing choice of a candidate gene 
supported by previous findings on the gene’s association with SZ. 
26 
 
 
PTPN21 
Marker Chr Location 
(bp) 
Gene 
Region 
Polymorphism GAIN  
p-value 
GAIN 
MAF 
CATIE 
p-value 
rs2274736 14 88008405 MM G/A 0.00106 0.354 0.01705 
rs2401751 14 88016375 MM A/G 0.00084 0.354 0.01883 
rs1864744 14 88020759 Intron C/G 0.00101 0.354 0.02501 
rs7160647 14 88043437 Intron T/C 0.00106 0.318 0.03853 
rs10138002 14 88046168 Intron A/G 0.00092 0.318 0.03834 
rs10150311 14 88046225 Intron G/A 0.00133 0.317 0.04164 
rs11847417 14 88046703 intron A/G 0.00104 0.318 0.03618 
 
EML5 
Marker Chr Location 
(bp) 
Gene 
Region 
Polymorphism GAIN 
 p-value 
GAIN 
MAF 
CATIE 
p-value 
rs10132509 14 88273534 Intron T/C 0.0183 0.448 0.02896 
rs17260415 14 88281726 Intron G/C 0.00650 0.280 0.04058 
rs10140896 14 88288291 Intron G/C 0.00892 0.464 0.02532 
rs12880096 14 88288568 Intron T/C 0.02032 0.463 0.02744 
rs7147796 14 88298322 Intron C/G 0.03648 0.469 0.01437 
rs7157149 14 88301598 Intron G/A 0.00812 0.273 0.01 
 
CMYA5 
Marker Chr Location 
(bp) 
Gene 
Region 
Polymorphism GAIN  
p-value 
GAIN 
MAF 
CATIE 
p-value 
rs6880680 5 79058467 Intron C/G 0.01146 0.075 0.01209 
rs3828611 5 79070418 MM G/C 0.02248 0.058 0.01704 
rs10043986 5 79131173 MM T/C 0.04148 0.135 0.02514 
rs4704591 5 79139217 UTR G/C 0.00036 0.385 0.03813 
 
NOS1AP 
Marker Chr Location 
(bp) 
Gene 
Region 
Polymorph
-ism 
GAIN  
p-value 
GAIN 
MAF 
CATIE 
p-value 
rs1123217 1 160307219 Intron G/C 0.00028 0.030 0.01887 
rs4656349 1 160316448 Intron G/A 0.01439 0.295 0.01278 
rs1337062 1 160329647 Intron C/T 0.01036 0.298 0.03275 
rs1337061 1 160329876 Intron A/G 0.00064 0.299 0.0346 
rs4657150 1 160368688 Intron C/T 0.02003 0.349 0.00914 
rs164151 1 160605586 Near gene C/T 0.02792 0.153 0.01037 
 
Table 1. All pre-select SNPs (GAIN & CATIE p<0.05) on candidate genes. Denotation: MAF,  
Minor allele frequency; MM, Missense Mutation; UTR, Untranslated region.
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Figure 4. Genomic Context of PTPN21 & EML5 Genes. PTPN21 and EML5 genes are 60 kb away, having ZC3H14 as the only 
gene between them.
PTPN21 EML5 TTC8 LOC390501 
ZC3H14 
Bp: 88001875 Bp: 88647320 
 3.3.2. EML5 
 From the GAIN study, 9 markers were included for PTPN21 with the p-value of less than 
0.05. In the CATIE study data, 10 markers were included for PTPN21 with the same criteria. 
One marker from the CATIE study was expelled as it did not meet the minimum HWE p-value 
(HW p-value > 0.01). There were 7 common markers between the two datasets that meet all 
requirements (Table 1). Out of the 7 common markers, there were 2 markers that cause missense 
mutations and they were included in the replication study; rs2274736 and rs2401751. The LD 
structure of the 7 common markers revealed that GAIN study (white samples only) grouped all 7 
markers in one block, whereas the CATIE study grouped them into two separate blocks (Figure 
5). Since the 2 missense mutation causing markers belong to only one of the two LD blocks in 
CATIE, one additional marker was selected from the LD block from which no marker has been 
chosen; rs10150311. Out of the 4 markers this LD block contained, rs10150311 was chosen as 
the tag SNP from the HaploView program. In sum, rs2274736, rs2401751, and rs10150311 were 
chosen to be tested for the PTPN21 gene (Table 3, Figure 10). 
 3.3.1. PTPN21 
 Detailed descriptions of the final list of markers selected and genotyped are listed in 
Table 3. The linkage disequilibrium (LD) structures spanning the candidate genes are indicated 
by the pseudo-color matrix, with darker shades indicating strong LD between a pair of 
chromosomal markers. Markers in strong LD are transmitted together on a chromosome, and 
thus can be used as proxies when searching for markers associated with disease risk (Petryshen 
et al., 2005). 
3.3. Linkage Disequilibrium Structures & Selected SNPs 
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 From the GAIN study white samples, 7 markers were included for EML5 with the p-
value of less than 0.05. In the CATIE study data, 8 markers were included for EML5 with the 
same criteria. There were 6 markers from each dataset that were in common with the other 
(Table 1), and all of these markers were shown to be form a tight LD block (Figure 6). However, 
out of the 6 markers, 4 did not meet the HWE cutoff (HW p-value > 0.01) for CATIE, and these 
markers were omitted from the study. This yielded 2 markers to be tested for the EML5 gene; 
rs17260415 and rs7147796 (Table 3, Figure 11). 
 3.3.3. CMYA5 
 Two of the three markers from the pre-select list of common significant markers between 
GAIN (white sample) and CATIE were chosen for the study, since they cause missense 
mutations (rs3828611 & rs10043986). The LD maps of all common markers between GAIN and 
CATIE datasets, regardless of their p-values, are shown in Figure 7 and 8. Rs4704591 was later 
added to the current study upon comparative analyses of all markers in the gene plus 20 KB 
upstream and downstream sequences in the GAIN and CATIE datasets. Table 2 shows 
rs4704591 as the marker with the lowest p-value from the combined analyses of GAIN and 
CATIE Caucasian datasets. In sum, rs3828611, rs10043986, and rs4704591 were chosen to be 
tested for the CMYA5 gene (Table 3, Figure 12). 
 3.3.4. NOS1AP 
 Using the HaploView program, a list of four tag SNPs were made for common markers 
between GAIN (white sample) and CATIE. However, two of the markers did not meet the HWE 
criteria for the CATIE study. Therefore, rs1123217 and rs1337062 were chosen to be tested. 
However, the company from which the markers were ordered from failed to manufacture 
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rs1337062. In sum, only rs1123217 was tested in the current study (Table 3, Figure 13). Figure 9 
shows LD maps of NOS1AP gene. 
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Marker GAIN Allelic 
P-value 
CATIE Allelic 
P-value 
GAIN & CATIE 
Combined Allelic P-value 
rs3087813 0.04322 0.31680 0.02482 
rs11960229 0.16513 0.28656 0.54371 
rs16877060 0.97432 0.78186 0.89937 
rs6870619 0.01205 0.06333 0.00161 
rs6880680 0.00942 0.02118 0.00068 
rs3828611 0.01799 0.06267 0.00310 
rs1991483 0.04335 0.08867 0.00904 
rs1428227 0.35889 0.25859 0.18088 
rs12655366 0.02697 0.61408 0.03383 
rs259124 0.30637 0.57222 0.25216 
rs259127 0.00633 0.30154 0.00445 
rs259129 0.00550 0.40468 0.00547 
rs259130 0.56299 0.60695 0.44294 
rs12657828 0.80540 0.00307 0.06365 
rs1129770 0.41612 0.33013 0.89374 
rs66682 0.16659 0.65761 0.16700 
rs3749683 0.20457 0.06374 0.89035 
rs10043986 0.04579 0.00411 0.00126 
rs7343 0.29541 0.30116 0.73649 
rs16877214 0.17563 0.09249 0.77931 
rs735639 0.02712 0.27799 0.19888 
rs259067 0.27719 0.31467 0.14943 
rs259066 0.21252 0.24477 0.09726 
rs259064 0.04508 0.55884 0.04532 
rs4704591 0.00036 0.03813 0.00004 
rs430866 0.07734 0.55305 0.06905 
rs17471700 0.12049 0.08197 0.70503 
 
Table 2. Comparative analyses of all markers of CMYA5 gene in GAIN & CATIE datasets. 
rs4704591 showed the lowest p-value. P-values were computed using the UNPHASED program 
and are slightly different from the p-values in Table 3, which were computed using the pLink 
program.
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Marker 
ID 
Marker Gene Polymorphism GAIN 
MAF 
GAIN  
p-value 
GAIN 
OR 
CATIE 
MAF 
CATIE 
p-value 
CATIE 
OR 
1 rs2274736 PTPN21 G/A 0.354 0.00106 0.8385  
[0.7455, 0.9431] 
0.390 0.01705 0.8368  
[0.7222, 0.9696] 
2 rs2401751 PTPN21 A/G 0.354 0.00084 0.8256  
[0.7335, 0.9292] 
0.347 0.01883 0.8157  
[0.7013, 0.9487 
3 rs10150311 PTPN21 G/A 0.317 0.00133 0.8341  
[0.7389, 0.9416] 
0.371 0.04164 0.8811 
[0.7588, 1.0232] 
4 rs17260415 EML5 G/C 0.280 0.00650 0.859  
[0.757, 0.9747] 
0.238 0.04058 0.8195  
[0.692, 0.9705] 
5 rs7147796 EML5 C/G 0.469 0.03648 1.1179  
[1, 1.2498] 
0.367 0.01437 1.0302  
[0.8866, 1.197] 
6 rs3828611 CMYA5 G/C 0.058 0.02248 1.3121  
[1.0476, 1.6434] 
0.101 0.01704 1.4255  
[0.9796, 2.074 
7 rs10043986 CMYA5 T/C 0.135 0.04148 0.8435  
[0.7133, 0.9973] 
0.091 0.02514 0.6718  
[0.5107, 0.8835] 
8 rs4704591 CMYA5 C/G 0.386 0.00036 0.813  
[0.7255, 0.9111] 
0.385 0.03812 0.8273  
[0.6915, 0.9898] 
9 rs1123217 NOS1AP G/C 0.030 0.00028 0.593  
[0.4458, 0.7889] 
0.124 0.01887 0.8293  
[0.6408, 1.073] 
MAF denotes minor allele frequency; OR denotes odds ratio.  
 
Table 3: Final list of SNPs. Marker characteristics in GAIN & CATIE datasets.
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LD Block Structures of Common Markers between GAIN & CATIE: PTPN21        
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Figure 5. LD Block Structures of Common Markers 
between GAIN & CATIE: PTPN21
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  LD Block Structures of Common Markers between GAIN & CATIE: EML5 
1) CATIE 
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Figure 6. LD Block Structures of Common Markers between GAIN & CATIE: EML5 
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LD Block Structures of Common Markers between GAIN & CATIE: CMYA5 
 
1) CATIE 
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1) rs3087813 
2) rs11960229 
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Figure 7. LD Block Structures of Common Markers between GAIN & CATIE: CMYA5 on CATIE 
platform. Common markers throughout the CMYA5 gene regardless of their p-values are shown here. 
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Figure 8. LD Block Structures of Common Markers between GAIN & CATIE: CMYA5 on GAIN 
platform. Common markers throughout the CMYA5 gene regardless of their p-values are shown here. 
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Figure 9. LD Block Structures of Common Markers between GAIN & CATIE: NOS1AP 
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5’                3’ 
 PTPN21 
 
 
Figure 10. SNP localization along the PTPN21 gene. Location of each investigated SNP within the PTPN21 gene with their 
respective allelic frequencies.
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Figure 11. SNP localization along the EML5 gene. Location of each investigated SNP within the EML5 gene with their respective 
allelic frequencies. 
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Figure 12. SNP localization along the CMYA5 gene. Location of each investigated SNP within the CMYA5 gene with their 
respective allelic frequencies. 
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Figure 13. SNP localization along the NOS1AP gene. Location of each investigated SNP within the NOS1AP gene with their 
respective allelic frequencies
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3.4. Statistical Results 
 Table 4 shows single-locus association results from the ISHDSF sample grouped by gene, 
and Table 5 shows those from the ICCSS sample. No marker was shown to be statistically 
significant (p <0.05) for ISHDSF and ICCSS samples. The lowest p-value achieved was 0.0883 
with rs10043986 for the CMYA5 gene in the ICCSS sample, but it is not statistically significant. 
 Three markers, rs3828611, rs10043986, and rs4704591, of the CMYA5 gene were 
additionally tested with the ITRIO sample. Marker rs4704591 from the CMYA5 gene was 
statistically significant in this sample (p = 0.04479) (Table 8). When the three replication 
samples (ICCSS + ISHDSF + ITRIO) are combined and analyzed, its significance improved (p = 
0.00388), as alleles are in the same direction for the samples (Table 8 & 9). On the other hand, 
the combined analysis of rs3828611 resulted in a less significant p-value, as the direction of the 
allele was flipped for the ITRIO sample, indicated by the value of odds ratio (Table 9). 
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Marker ID Marker Gene Polymorphism MAF p-value OR 
1 rs2274736 PTPN21 G/A 0.355 0.8848 0.740 [0.451, 1.212] 
2 rs2401751 PTPN21 A/G 0.349 0.8108 0.775 [0.468, 1.283] 
3 rs10150311 PTPN21 G/A 0.314 0.8446 0.739 [0.451, 1.212] 
4 rs17260415 EML5 G/C 0.282 0.6766 0.686 [0.411, 1.142] 
5 rs7147796 EML5 C/G 0.472 0.44 1.358 [0.865, 2.131] 
6 rs3828611 CMYA5 G/C 0.061 0.3359 1.111 [0.451, 2.741] 
7 rs10043986 CMYA5 T/C 0.123 0.7467 1         [0.554, 1.806]   
8 rs4704591 CMYA5 C/G 0.376 0.0936 0.659 [0.418, 1.037] 
9 rs1123217 NOS1AP G/C 0.055 0.8657 1         [0.351, 2.851] 
         MAF denotes minor allele frequency; OR denotes odds ratio. 
 
Table 4. Single marker associations (p values) of the ISHDSF sample 
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Marker ID Marker Gene Polymorphism MAF p-value OR 
1 rs2274736 PTPN21 G/A 0.35 0.52585 0.936   [0.7911, 1.107] 
2 rs2401751 PTPN21 A/G 0.345 0.67394 0.9503 [0.804, 1.123] 
3 rs10150311 PTPN21 G/A 0.317 0.57809 0.9496 [0.8006, 1.126] 
4 rs17260415 EML5 G/C 0.286 0.23790 0.9952 [0.8349, 1.186] 
5 rs7147796 EML5 C/G 0.478 0.6808 1.044   [0.8895, 1.225] 
6 rs3828611 CMYA5 G/C 0.060 0.67949 1.059   [0.7579, 1.479] 
7 rs10043986 CMYA5 T/C 0.130 0.08830 0.8149 [0.6439, 1.031] 
8 rs4704591 CMYA5 C/G 0.355 0.19820 0.9008 [0.7632, 1.063] 
9 rs1123217 NOS1AP G/C 0.038 0.73411 0.8977 [0.5944, 1.356] 
       MAF denotes minor allele frequency; OR denotes odds ratio. 
 
Table 5. Single marker associations (p values) of the ICCSS sample 
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Marker ID Marker Gene Polymorphism p-value 
1 rs2274736 PTPN21 G/A 0.35410 
2 rs2401751 PTPN21 A/G 0.23447 
3 rs10150311 PTPN21 G/A 0.13893 
4 rs17260415 EML5 G/C 0.19597 
5 rs7147796 EML5 C/G 0.08274 
6 rs3828611 CMYA5 G/C 0.87345 
7 rs10043986 CMYA5 T/C 0.42478 
8 rs4704591 CMYA5 C/G 0.00388 
9 rs1123217 NOS1AP G/C 0.41842 
                   MAF denotes minor allele frequency. 
 
Table 6. Single marker associations (p values) of the combined replication for all markers. For CMYA5 gene, ICCSS + ISHDSF 
+ ITRIO; for all other genes, ICCSS + ISHDSF.
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SZ and CON; allele frequency in schizophrenia and controls.  
Table 7. CMYA5 Gene Combined Discovery Sample (GAIN & CATIE) Analyses. 
   Discovery 1  
(GAIN -Caucasian) 
Discovery 2  
(CATIE - Caucasian) 
Discovery Combined  
(1+2) 
 
   Cases n = 1172 
Controls n = 1378 
Missing phenotype n = 51 
Cases n = 492 
Controls n = 523 
Missing phenotype n = 0 
Cases n = 1686 
Controls n = 1901 
Missing phenotype n = 51 
Chr./Mb SNP Minor 
Allele 
SZ CON Allelic 
P-value 
SZ CON Allelic 
P-value 
SZ CON Allelic 
P-value 
5/79070418 rs3828611 G 0.074 0.058 0.02248 0.068 0.049 0.01704 0.074 0.056 0.00310 
5/79131173 rs10043986 T 0.116 0.135 0.04148 0.098 0.139 0.02514 0.110 0.136 0.00126 
5/79139227 rs4704591 C 0.359 0.408 0.00036 0.362 0.406 0.03813 0.360 0.408 0.00004 
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Replication 1 (ICCSS) 
 
Replication 2 
(ISHDSF) 
 
Replication 3 (ITRIO) 
 Replications 
Combined  
(1+2 +3)  
  Cases n = 657 
Controls n = 411 
Cases n = 522 
Controls n = 869 
Cases n = 216 
Controls n = 372 
Cases n = 1395 
Controls n = 1652 
Chr./Mb SNP MA 
SZ 
MA 
CON 
P-value MA
SZ 
MA 
CON 
P-value MA 
SZ 
MA 
CON 
P-value MA 
SZ 
MA 
CON 
P-
value 
5/79070418 rs3828611 0.061 0.058 0.67949 N/A N/A 0.3359 0.041 0.052 0.48179 0.058 0.057 0.8734
5 
5/79131173 rs10043986 0.119 0.142 0.08830 N/A N/A 0.7467 0.094 0.010 0.79855 0.119 0.142 0.4247
8 
5/79139227 rs4704591 0.343 0.368 0.19820 N/A N/A 0.0936 0.346 0.419 0.04479 0.343 0.367 0.0038
8 
MA SZ and MA CON; minor allele frequency in schizophrenia and controls.  
Table 8. CMYA5 Gene Combined Replication Sample (ICCSS + ISHDSF + ITRIO) Analyses. Single marker associations were 
calculated for ICCSS, ISHDSF, and ITRIO samples respectively and also for the combined samples (ICCSS + ISHDSF + ITRIO). 
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Marker 
ID Marker GAIN OR CATIE OR ICCSS OR TRIADS OR ISHDSF OR 
1 rs2274736 
0.8385  
[0.7455, 0.9431] 
0.8368  
[0.7222, 0.9696] 
0.936  
[0.7911, 1.107] N/A 
0.7396  
[0.4514, 1.212] 
2 rs2401751 
0.8256  
[0.7335, 0.9292] 
0.8157  
[0.7013, 0.9487] 
0.9503  
[0.804, 1.123] N/A 
0.775  
[0.4681, 1.283] 
3 rs10150311 
0.8341  
[0.7389, 0.9416] 
0.8811  
[0.7588, 1.0232] 
0.9496  
[0.8006, 1.126] N/A 
0.7393  
[0.4507, 1.212] 
4 rs17260415 
0.859  
[0.757, 0.9747] 
0.8195  
[0.692, 0.9705] 
0.9952  
[0.8349, 1.186] N/A 
0.6855  
[0.4114, 1.142] 
5 rs7147796 
1.1179  
[1, 1.2498] 
1.0302  
[0.8866, 1.197] 
1.044  
[0.8895, 1.225] N/A 
1.358  
[0.8649, 2.131] 
6 rs3828611 
1.3121  
[1.0476, 1.6434] 
1.4255  
[0.9796, 2.0743] 
1.059  
[0.7579, 1.479] 
0.7778  
[0.3868, 1.564] 
1.111  
[0.4505, 2.741]  
7 rs10043986 
0.8435  
[0.7133, 0.9973] 
0.6718  
[0.5107, 0.8835] 
 0.8149  
[0.6439, 1.031] 
0.9355  
[0.5637, 1.552] 
1  
[0.5538, 1.806]   
8 rs4704591 
0.813  
[0.7255, 0.9111] 
0.8273  
[0.6915, 0.9898] 
0.9008  
[0.7632, 1.063] 
0.747  
[0.5553, 1.005] 
0.6585  
[0.4182, 1.037] 
9 rs1123217 
0.593  
[0.4458, 0.7889] 
0.8293  
[0.6408, 1.073] 
0.8977  
[0.5944, 1.356] N/A 
1  
[0.3508, 2.851] 
OR denotes odds ratio. Brackets indicate 95% confidence intervals for the OR. 
 
Table 9. Odds Ratio Analyses of All Samples. All samples were analyzed using UNPHASED v.3.1. 
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CHAPTER 4: DISCUSSION 
 The SZ research community has produced a plethora of research data involving a large 
number of candidate genes and various ethnic groups as samples. As this trend continues, it has 
become increasingly important to devise methods to effectively and systematically integrate 
accumulated data in order to select a list of “prioritized” candidate genes (Le-Niculescu et al., 
2007). Publicly available genome-wide association studies such as GAIN and CATIE introduced 
in this study not only cover markers across the genome, but also provide information for a large 
number of samples. The current study takes an approach of selecting candidate genes by relying 
on statistical evidence from not just one set of GWAS data, but on two. This study design 
assumed the hypothesis that p-values from GWAS datasets suggest an increased likelihood of 
such markers being replicated in other populations. Although each of these large GWAS datasets 
is able to provide immensely useful information on its own, a successful integration of the 
datasets increases the chance of selecting promising candidate genes for further examinations by 
basing the selection upon evidence from independent samples. This is likely to improve the 
reliability for candidate selection. 
 From the results of the current study, we successfully replicated one of the 9 markers 
tested, or one of 4 candidate genes. Our performance is slightly better than random selection. 
However, it is difficult to attribute the better performance strictly to  statistical evidence (p-
value) from GWAS datasets, because, judging from the p-values of the markers selected from 
both GAIN and CATIE, rs4704591, the one marker successfully confirmed, is not the best one 
among the 9 selected markers (see data in Table 3). 
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 Although the correctness of our hypothesis remains uncertain, the scarcity of statistically 
significant findings from the current study may be partially accounted for by the lack of power 
due to small replication sample sizes. A review of odds ratios (Table 9) reveals that for some of 
the markers genotyped, the sample sizes were not efficient to detect their effects. In addition to 
the statistical significance found with rs4704591 (CMYA5 gene) in the ITRIO sample, modest 
effects observed in other samples for the same marker were seen to be in the same direction on 
the same allele, which led to the p-value of the combined analyses of all replication samples to 
be relatively small (p-value = 0.00388). Thus, more replications are needed to verify CMYA5 as 
a true susceptibility gene for Schizophrenia and also for other genes in the study. If additional 
replications still produce negative associations of such genes with SZ, such reports provide 
useful information so that the next generation of research studies can be appropriately focused. 
Schizophrenia is thought to be caused by a large number of contributing loci with subtle 
effects, interactions (gene-gene, gene-environment, intralocus), complex single locus effects, or 
parent-of-origin or epigenetic effects (The Psychiatric GWAS Consortium Steering Committee, 
2009). This fact points us to areas in which future studies can improve on. One could argue that 
selecting significant p-values from a simple additive genetics model of GWAS may not be 
sufficient for discovering candidate genes and SNPs for SZ, which is thought to not conform to 
this model. In addition, whereas GWAS assess only a subset of genetic variants (SNPs and 
CNVs), there are many other types of genetic variants that may be important and that could be 
systematically incorporated into candidate selection. Another possible area of error may be found 
in analyzing the combined CATIE and GAIN datasets. A direct overlap between different 
platforms is often modest at best, and these platforms must be made comparable in terms of 
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SNPs included, subjects, and other factors of bias such as population stratification, cryptic 
relatedness or genotyping batch effects (The Psychiatric GWAS Consortium Steering Committee, 
2009). In the current study, efforts were made to eliminate ethnic heterogeneity of subjects 
present in the CATIE study that is not comparable with the GAIN study by employing only 
Caucasian samples for our analyses. However, other factors of platform compatibility were not 
resolved, and future studies may benefit from considering the issue. 
 Out of the four genes investigated for association with schizophrenia in the current study, 
a promising result emerged from the CMYA5 gene. As for the markers that failed to show 
significance, the knowledge of what a disorder is not, has its value in appropriately focusing the 
next generation of research. The positive association found with CMYA5 is exciting, as the 
discovery was made with the presence of a compelling association without an obvious biological 
function of the gene in the nervous system. CMYA5 being a binding partner for dysbindin in 
muscles sheds light on the effects of glutamatergic neurotransmission on the pathophysiology of 
schizophrenia in which dysbindin is involved. Glutamatergic neurons innervate the cortex, 
limbic regions, and striatum as a part of excitatory afferent and efferent systems. A family of 
glutamate-gated ion channels that depolarize neurons mediate the postsynaptic actions of 
glutamate. Psychotomimetics such as phencyclidine act on one of these receptors, the N-methyl-
D-asparate (NMDA) receptor, and reproduce schizophrenic symptoms in normal individuals. It 
has been suspected that glutamatergic dysfunction is especially relevant to schizophrenia forms 
in which negative symptoms, cognitive deficits, and deterioration are prominent. In addition, 
drugs that enhance NMDA-receptor functions reduce such symptoms in chronic schizophrenia 
patients (Coyle, 1996). The association made with the CMYA5 gene gives future researchers a 
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starting point to determine how variations in related glutamatergic pathways or genetic regions 
affect vulnerability to schizophrenia. Currently, our laboratory is collaborating with other 
institutions in order to replicate our results on the CMYA5 gene in other samples. Long-term 
goals of the current study may enable clinicians to prevent schizophrenia, or to identify cases 
earlier for more efficacious treatments which may lead to decreased mortality. 
 For the GWAS data based on individual genotyping thus far reported, the total combined 
sample sizes are still small (fewer than 1500 cases), and the power to identify small genetic 
effects is limited (Williams et al., 2009). The current study made an improvement on previous 
GWAS-based studies by increasing the discovery sample size to better approximate marker 
significances. Although it is inconclusive how beneficial this approach was in the current study, 
as a result, we identified CMYA5 to be associated with schizophrenia in our Irish samples. The 
finding provides a cause for optimism that larger scale of future studies will be able to identify 
additional loci associated with schizophrenia. 
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